Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease.
McShane C, Varley R, Fennessy A, Byron C, Campion JR, Hazel K, Costigan C, Ring E, Marrinan A, Judge C, Sugrue K, Cullen G, Dunne C, Hartery K, Iacucci M, Kelly O, Leyden J, McKiernan S, O'Toole A, Sheridan J, Slattery E, Boland K, McNamara D, Egan L, Ghosh S, Doherty G, McCarthy J, Kevans D. McShane C, et al. Among authors: kevans d. Dig Liver Dis. 2024 Sep 21:S1590-8658(24)00973-3. doi: 10.1016/j.dld.2024.08.055. Online ahead of print. Dig Liver Dis. 2024. PMID: 39307602
Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease.
Judge C, McGettigan N, Ryan T, Hazel K, Singh P, Parihar V, Stack R, O'Connor A, Dunne C, Cullen G, Egan L, Harewood G, MacCarthy F, McKiernan S, Mulcahy H, Murray F, Patchett S, Sheridan J, Cheriyan D, Farrell R, Keohane J, Kelly O, McNamara D, Ryan B, O'Morain C, Sengupta S, O'Toole A, Buckley M, McCarthy J, Doherty G, Kevans D, Slattery E. Judge C, et al. Among authors: kevans d. Scand J Gastroenterol. 2020 Jul;55(7):786-794. doi: 10.1080/00365521.2020.1779340. Epub 2020 Jun 16. Scand J Gastroenterol. 2020. PMID: 32544012
Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772).
Sheridan J, Coe CA, Doran P, Egan L, Cullen G, Kevans D, Leyden J, Galligan M, O'Toole A, McCarthy J, Doherty G. Sheridan J, et al. Among authors: kevans d. BMJ Open Gastroenterol. 2018 Jan 11;5(1):e000174. doi: 10.1136/bmjgast-2017-000174. eCollection 2018. BMJ Open Gastroenterol. 2018. PMID: 29379609 Free PMC article.
Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
O'Connell J, Rowan C, Stack R, Harkin G, Parihar V, Chan G, Breslin N, Cullen G, Dunne C, Egan L, Harewood G, Leyden J, MacCarthy F, MacMathuna P, Mahmud N, McKiernan S, McNamara D, Mulcahy H, Murray F, O'Connor A, O'Toole A, Patchett S, Ryan B, Sheridan J, Slattery E, Doherty G, Kevans D. O'Connell J, et al. Among authors: kevans d. Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1019-1026. doi: 10.1097/MEG.0000000000001177. Eur J Gastroenterol Hepatol. 2018. PMID: 29878945
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36152897 Free article.
Treatment de-escalation in Crohn's disease.
McShane C, Kevans D. McShane C, et al. Among authors: kevans d. Lancet Gastroenterol Hepatol. 2023 May;8(5):401. doi: 10.1016/S2468-1253(23)00073-0. Lancet Gastroenterol Hepatol. 2023. PMID: 37030299 No abstract available.
Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction.
Gibson DJ, Doherty J, McNally M, Campion J, Keegan D, Keogh A, Kennedy U, Byrne K, Egan LJ, McKiernan S, MacCarthy F, Sengupta S, Sheridan J, Mulcahy HE, Cullen G, Slattery E, Kevans D, Doherty GA. Gibson DJ, et al. Among authors: kevans d. Frontline Gastroenterol. 2019 Dec 13;11(6):441-447. doi: 10.1136/flgastro-2019-101335. eCollection 2020 Oct. Frontline Gastroenterol. 2019. PMID: 33104766 Free PMC article.
Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis.
O'Connell J, Doherty J, Buckley A, Cormican D, Dunne C, Hartery K, Larkin J, MacCarthy F, McCormick P, McKiernan S, Mehigan B, Muldoon C, Ryan C, O'Sullivan J, Kevans D. O'Connell J, et al. Among authors: kevans d. Intest Res. 2022 Jul;20(3):381-385. doi: 10.5217/ir.2021.00073. Epub 2022 Mar 11. Intest Res. 2022. PMID: 35263959 Free PMC article. No abstract available.
Characteristics and outcomes of acute colitis diagnosed on cross-sectional imaging presenting via the emergency department in an Irish academic medical centre.
O'Connell J, Keohane S, McGreal-Bellone A, McDonagh P, Naimimohasses S, Kennedy U, Dunne C, Hartery K, Larkin J, MacCarthy F, Meaney J, McKiernan S, Norris S, O'Toole D, Kevans D. O'Connell J, et al. Among authors: kevans d. Ir J Med Sci. 2020 Aug;189(3):1115-1121. doi: 10.1007/s11845-019-02162-w. Epub 2020 Jan 10. Ir J Med Sci. 2020. PMID: 31925651
52 results